1001522-07-1

Basic information

• Product Name: 5-tert-butyl-2-(3-chloro-4-fluorophenyl)pyrazol-3-amine
• Synonyms: 5-tert-butyl-2-(3-chloro-4-fluorophenyl)pyrazol-3-amine
• CAS NO: 1001522-07-1
• Molecular Weight: 267.734
• Mol File: 1001522-07-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-tert-butyl-2-(3-chloro-4-fluorophenyl)pyrazol-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-tert-butyl-2-(3-chloro-4-fluorophenyl)pyrazol-3-amine(1001522-07-1)
• EPA Substance Registry System: 5-tert-butyl-2-(3-chloro-4-fluorophenyl)pyrazol-3-amine(1001522-07-1)

Safety Data

• Hazardous Substances Data: 1001522-07-1(Hazardous Substances Data)

Upstream product

• 59997-51-2 trimethylacetylacetonitrile 
• 175135-74-7 (3-chloro-4-fluorophenyl)hydrazine hydrochloride 
• 175135-74-7 3-chloro-4-fluorophenylhydrazine hydrochloride 

Downstream Products

• 1071964-59-4 1-(3-tert-butyl-1-(3-chloro-4-fluorophenyl)-1H-pyrazol-5-yl)-3-(5-(2-morpholinoethoxy)-2H-chromen-8-yl)urea 
• 1255040-43-7 N-((3-tert-butyl-1-(3-chloro-4-fluorophenyl)-1H-pyrazol-5-yl)methyl)-2-(3-fluoro-4-(methylsulphonamido)phenyl)propanamide 
• 1254713-64-8 (3-tert-butyl-1-(3-chloro-4-fluorophenyl)-1H-pyrazol-5-yl)methanamine 

Relevant articles and documents

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP) = 0.1 nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.